Glenmark Pharmaceuticals
- Market cap
- ₹ 60,103 Cr.
- P/E
- 20.8x
- P/B
- 5.9x
- 52-week range
- 1,792.6 – 2,537.6
- ROE
- 24%
- ROCE
- 40%
- Dividend yield
- 0.2%
- Debt / equity
- 0.06
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Glenmark Pharmaceuticals Limited is an India-based, research-led, global pharmaceutical company. The Company hosts a diverse portfolio spanning branded, generics, and over-the-counter (OTC) segments. The Company is focused on the therapy areas of Respiratory, Dermatology and Oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. The Company’s offerings include complex injectables and biologics, oral solids, liquids, topical products, respiratory mdi1/dpi2/nasal sprays. It is focused on developing products for markets such as India, Russia & CIS, Brazil, Asia and Africa. Its brands include RYALTRIS and SALMEX / ASTHMEX. RYALTRIS, the Company's first global branded specialty drug for treating symptoms of seasonal allergic rhinitis. The Company's subsidiaries include Glenmark Pharmaceuticals Inc., Ichnos Sciences Inc., and Glenmark Holding SA.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Glenmark Pharmaceuticals against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)20.8 against a typical 34.3: cheaper than most peers (1st = cheapest).65th of 220
- Sales growth+23.1% against a typical +15.6% from a year earlier.70th of 197
- Profit growth+927.7% against a typical +18.9% from a year earlier.7th of 160
- Share price, 3 months+1.7% against a typical −0.5%.91st of 200
- Size₹ 60,102.6 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).10th of 199
Latest announcements
Exchange filings and their impact on the company.
- Glenmark launched OTC Adapalene pump packs in the US targeting a $45.8m market, a small incremental positive.
Glenmark Therapeutics Inc., USA launched Adapalene Gel USP, 0.1% (OTC), comparable to Differin Gel 0.1%, in new 15g and 45g pump packs on Amazon and Walmart.com. The total Differin Gel 0.1% OTC market is about $45.8 million in annual US sales per Nielsen data to September 5, 2026. The launch expands Glenmark's US dermatology and consumer health portfolio with a convenient pack, but the sales addition is small relative to Glenmark's Rs 16,983 crore FY26 revenue.
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
High safety
Rated AA+ to AA by 2 agencies- All agencies agree and none has raised a warning.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| India Ratings | IND AA+; IND A1+ | Stable | 10 Sep 2026 |
| CRISIL | Crisil AA | Positive | 12 Aug 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 10 Sep 2026 | ▲ Upgrade | IND AA+ | — | India Ratings | ₹ 1,850 Cr. | |
| 12 Aug 2026 | Reaffirmed | Crisil AA | — | CRISIL | ₹ 1,850 Cr. | |
| 11 Feb 2026 | Reaffirmed | Crisil AA | — | CRISIL | ₹ 1,850 Cr. | |
| 18 Sep 2025 | Rating action | Crisil AA | — | CRISIL | ₹ 1,850 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 5 Nov 2026Upcoming | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 31 Jul 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 29 May 2026 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2026 and dividend |
| 30 Jan 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 14 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 26 Sep 2025 | Dividend | To consider and approve payment of interim dividend |
| 14 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended June 30, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,207 | 2,507 | 3,063 | 3,244 | 3,434 | 3,388 | 3,256 | 3,264 | 6,047 | 3,901 | 3,771 | 4,018 |
| Expenses | 2,745 | 2,715 | 2,559 | 2,656 | 2,832 | 2,787 | 2,695 | 2,684 | 3,687 | 3,031 | 3,008 | 3,214 |
| Operating Profit | 462 | −209 | 504 | 588 | 602 | 600 | 561 | 581 | 2,360 | 870 | 763 | 805 |
| OPM % | 14% | −8% | 16% | 18% | 18% | 18% | 17% | 18% | 39% | 22% | 20% | 20% |
| Other Income | −205 | 87 | 351 | 31 | 39 | 31 | −361 | −297 | −1,184 | −140 | −184 | 66 |
| Interest | 121 | 134 | 149 | 40 | 48 | 52 | 67 | 58 | 66 | 41 | 43 | 54 |
| Depreciation | 141 | 147 | 151 | 118 | 120 | 123 | 125 | 130 | 141 | 154 | 148 | 173 |
| Profit before tax | −6 | −403 | 555 | 462 | 473 | 456 | 8 | 96 | 967 | 534 | 388 | 643 |
| Tax % | 997% | −18% | 319% | 26% | 25% | 24% | 45% | 51% | 37% | 24% | 22% | 25% |
| Net Profit | −62 | −331 | −1,214 | 340 | 354 | 348 | 4 | 47 | 610 | 403 | 301 | 483 |
| EPS in Rs | −2.9 | −12.45 | −43.17 | 12.06 | 12.55 | 12.33 | 0.16 | 1.66 | 21.63 | 14.29 | 10.68 | 17.11 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 8%
- 5 Years
- 9%
- 3 Years
- 14%
- TTM
- 33%
- 10 Years
- 12%
- 5 Years
- 19%
- 3 Years
- 61%
- TTM
- 134%
- 10 Years
- 11%
- 5 Years
- 34%
- 3 Years
- 45%
- TTM
- —
- 10 Years
- 7%
- 5 Years
- 2%
- 3 Years
- −3%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Glenmark Pharmaceuticals | ₹ 2,300.00 | ₹ 60,103 Cr. | 20.8x | 5.9x | 24% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Glenn Mario Saldanha
- Executive Chairman of the Board, Managing Director
- Anurag Mantri
- Global Chief Financial Officer, Executive Director
- Rashmi Khandelwal
- Compliance Officer, Company Secretary
- Cherylann Pinto
- Executive Director - Corporate Services
Prices are delayed and for information only. Nothing on this page is investment advice.